This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Otonomy Dividend

Dividend criteria checks 0/6

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.4%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$0.76
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

Shareholders Will Probably Hold Off On Increasing Otonomy, Inc.'s (NASDAQ:OTIC) CEO Compensation For The Time Being

Jun 16

Otonomy shares rise after initiating expansion of early-stage OTO-413 hearing loss trial

Jun 15

Is Otonomy (NASDAQ:OTIC) Using Debt In A Risky Way?

Feb 02

Otonomy And Its Efforts At Resurrecting Itself

Jan 12

Are Institutions Heavily Invested In Otonomy, Inc.'s (NASDAQ:OTIC) Shares?

Dec 11

Otonomy (OTIC) Investor Presentation - Slideshow

Dec 02

Otonomy issues update for Otividex and OTO-313

Nov 30

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if OTIC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OTIC's dividend payments have been increasing.

Dividend Yield vs Market

Otonomy Dividend Yield vs Market

How does OTIC dividend yield compare to the market?
Segment	Dividend Yield
Company (OTIC)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.8%
Industry Average (Pharmaceuticals)	2.4%
Analyst forecast in 3 Years (OTIC)	n/a

Notable Dividend: Unable to evaluate OTIC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OTIC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as OTIC has not reported any payouts.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

This company listing is no longer active

Otonomy Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Otonomy, Inc. Announces Executive Changes

Otonomy, Inc.(OTCPK:OTIC) dropped from Russell 3000E Value Index

Otonomy, Inc. Plans Reduce Its Workforce

Price target increased to US$9.00

Otonomy, Inc Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss

Otonomy Receives Non-Compliance Letter from Nasdaq

Otonomy, Inc. Announces Departure of Robert Michael Savel II, as Chief Technical Officer Effective August 15, 2022

Price target decreased to US$5.83

Otonomy Reports Results from Phase 2 Clinical Trial of Oto-313 in Patients with Tinnitus

Otonomy crashes 73% as mid-stage trial for tinnitus candidate fails

Otonomy GAAP EPS of -$0.19 beats by $0.01

Otonomy, Inc. to Report Q2, 2022 Results on Jul 25, 2022

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.23 loss in 1Q 2021)

Otonomy, Inc. to Report Q1, 2022 Results on May 09, 2022

Price target increased to US$6.50

Price target increased to US$6.50

Otonomy, Inc. Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss

Otonomy: Hearing Loss And Tinnitus Data In 2022

Full year 2021 earnings: EPS exceeds analyst expectations

Otonomy, Inc. Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus

Otonomy, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Otonomy Reports Corporate and Product Pipeline Update

Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.22 loss in 3Q 2020)

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.19 loss per share (vs US$0.37 loss in 2Q 2020)

Otonomy Initiates Expansion of Phase 1/2 Clinical Trial for Oto-413 in Hearing Loss

Shareholders Will Probably Hold Off On Increasing Otonomy, Inc.'s (NASDAQ:OTIC) CEO Compensation For The Time Being

Otonomy shares rise after initiating expansion of early-stage OTO-413 hearing loss trial

ALK-Abelló A/S (CPSE:ALK B) acquired OTIPRIO from Otonomy, Inc. (NasdaqGS:OTIC).

Consensus revenue estimates increase to US$183.8k

Otonomy, Inc. and Applied Genetic Technologies Corporation Present Preclinical Proof-Of-Concept Results for Oto-825 Gene Therapy At ASGCT Annual Meeting

First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.38 loss in 1Q 2020)

Otonomy, Inc. Announces to Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting

Consensus forecasts updated

Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's Disease

New 90-day low: US$3.00

Analysts lower revenue estimates to US$91.7k

Revenue and earnings miss expectations

Full year 2020 earnings released: US$1.10 loss per share (vs US$1.45 loss in FY 2019)

Otonomy, Inc. to Report Q4, 2020 Results on Feb 11, 2021

Is Otonomy (NASDAQ:OTIC) Using Debt In A Risky Way?

Otonomy And Its Efforts At Resurrecting Itself

Otonomy, Inc. Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-413 in Patients with Hearing Loss

Price target raised to US$10.80

New 90-day high: US$5.98

Are Institutions Heavily Invested In Otonomy, Inc.'s (NASDAQ:OTIC) Shares?

Otonomy (OTIC) Investor Presentation - Slideshow

Otonomy, Inc. Provides Update on Otividex® and Oto-313 Programs

New 90-day high: US$4.79

Otonomy issues update for Otividex and OTO-313

Revenue and earnings miss expectations

Third quarter 2020 earnings released: US$0.22 loss per share

Otonomy, Inc. to Report Q3, 2020 Results on Nov 04, 2020

Otonomy Completes Patient Enrollment for Phase 3 Trial of OTIVIDEX in Ménière’s Disease

New 90-day high: US$4.44

New 90-day high - US$4.36

First half earnings released

Otonomy, Inc. to Report Q2, 2020 Results on Aug 04, 2020

Otonomy, Inc. has completed a Follow-on Equity Offering in the amount of $60.121 million.

Otonomy, Inc.(NasdaqGS:OTIC) dropped from Russell Microcap Value Index

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies